EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life

Juveriya Farooq, M M Sana, P M Chetana, Mansour Almuqbil, Nagapati Prabhakar Bhat, Rokeya Sultana, UmaimaFarheen Khaiser, Syed Mohammed Basheeruddin Asdaq, Mutlaq Eidhah M Almalki, Amro Mohammed Sawadi Khormi, Salem Ahmad Albraiki, Moneer E Almadani

Saudi Pharmaceutical Journal · 2023-08 · 31 (8) · 101668

DOI: 10.1016/j.jsps.2023.06.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Saudi Pharmaceutical Journal, 2023-08. Verfasst von Juveriya Farooq und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Shree Devi College of Pharmacy, Mangaluru, 574142, Karnataka, India. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: King Saud University, AlMaarefa University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple prescriptions for different medications may be needed for chronic conditions, increasing the risk of polypharmacy. The WHO defined polypharmacy as "the administration of many drugs at the same time or the administration of an excessive number of drugs". The primary goal of this study was to evaluate polypharmacy in patients with chronic liver disease and to identify potential drug-drug interactions associated with it. A cross-sectional study was conducted at a tertiary care hospital in Mangalore, Karnataka, for six months, from November 2020 to April 2021. The study involved 118 patients with chronic liver disease from various age groups. Data was gathered by analyzing patients' medical records kept on the ward and interviewing them individually. In admission and discharge prescriptions, polypharmacy was examined. Online interaction checkers from Drugs.com and Medscape were used to interpret potential drug-drug interactions. The SF-36 and Chronic Liver Disease Questionnaire were used to measure the quality of life. The data obtained were analyzed statistically to determine the significant correlation. The number of prescribed drugs was significantly correlated (P = 0.018) with the severity of liver disease in Child-Pugh categories B and C. Additionally, moderate polypharmacy reduced quality of life (P < 0.05), and the physical health category was significantly associated with disease severity (P < 0.05). Drug-drug interactions were found in 108 out of the 118 examined prescriptions, totaling 586 interactions in the admission list and 405 interactions in the discharge list. If the potentially serious main drug interaction identified in this study is not well monitored, it could lead to a serious, potentially fatal health condition. Despite being advised, safety is not always guaranteed by liver enzyme monitoring. Therefore, healthcare providers must take additional precautions to avoid inappropriate prescribing, minimize side effects, and ensure drug safety.

Schlagwörter

Stichwörter der Autor:innen

Chronic liver diseaseCirrhosisDrug-drug interactionPolypharmacyQuality of life

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Shree Devi College of Pharmacy, Mangaluru, 574142, Karnataka, India.
  • Department of pharmacology, Yenepoya (Deemed to be) University, Deralakatte, 575018, Karnataka, India.
  • Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
  • Department of Pharmacognosy, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be) University, Deralakatte, 575018, Karnataka, India.
  • Department of Pharmacy Practice, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be) University, Deralakatte, 575018, Karnataka, India.
  • Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia.

Förderung

  • King Saud University
  • AlMaarefa University

Zitieren

APA

Farooq, J., Sana, M. M., Chetana, P. M., Almuqbil, M., Prabhakar Bhat, N., Sultana, R., Khaiser, U., Mohammed Basheeruddin Asdaq, S., Almalki, M. E. M., Mohammed Sawadi Khormi, A., Ahmad Albraiki, S., & Almadani, M. E. (2023). Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life. Saudi Pharmaceutical Journal, 31(8), 101668. https://doi.org/10.1016/j.jsps.2023.06.001

Vancouver

Farooq J, Sana MM, Chetana PM, Almuqbil M, Prabhakar Bhat N, Sultana R, et al. Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life. Saudi Pharmaceutical Journal. 2023;31(8):101668. doi:10.1016/j.jsps.2023.06.001

BibTeX
@article{Farooq2023,
  author = {Farooq, Juveriya and Sana, M M and Chetana, P M and Almuqbil, Mansour and Prabhakar Bhat, Nagapati and Sultana, Rokeya and Khaiser, UmaimaFarheen and Mohammed Basheeruddin Asdaq, Syed and Almalki, Mutlaq Eidhah M and Mohammed Sawadi Khormi, Amro and Ahmad Albraiki, Salem and Almadani, Moneer E},
  title = {Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life},
  journal = {Saudi Pharmaceutical Journal},
  year = {2023},
  volume = {31},
  number = {8},
  pages = {101668},
  doi = {10.1016/j.jsps.2023.06.001}
}
Kostenlos starten →